

Bromodomain Containing Protein 2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/B249F5A05EB7EN.html>

Date: February 2020

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: B249F5A05EB7EN

Abstracts

Bromodomain Containing Protein 2 - Pipeline Review, H1 2020

SUMMARY

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene.

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Immunology, Musculoskeletal Disorders and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Fibrosis, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Leukemia, Lung Cancer, Multiple Myeloma (Kahler

Disease), Myelofibrosis, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Small-Cell Lung Cancer, Systemic Lupus Erythematosus and Vitiligo.

The latest report Bromodomain Containing Protein 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)

The report reviews Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics and enlists all their major and minor projects

The report assesses Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or

O27.1.1 or BRD2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Overview

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Companies Involved in Therapeutics Development

AbbVie Inc

Amgen Inc

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Constellation Pharmaceuticals Inc

Ningbo Wenda Pharma

Zenith Epigenetics Ltd

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Drug Profiles

ABBV-744 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOS-475 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-95775 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-0610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NHWD-870 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-19796 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-20798 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-7770 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QCA-570 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEN-3694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Dormant Products

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Discontinued Products

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Product Development Milestones

Featured News & Press Releases

Jan 07, 2020: Zenith Epigenetics receives US\$5 million milestone payment from Newsoara

Dec 19, 2019: Zenith Epigenetics announces clinical advancement of ZEN-3694

Dec 09, 2019: Constellation Pharmaceuticals provides updated preliminary data from MANIFEST clinical trial with CPI-0610 in oral and poster presentations at ASH

Dec 02, 2019: Constellation Pharmaceuticals to host analyst/investor meeting at ASH to discuss updated preliminary data from the MANIFEST clinical trial with CPI-0610

Nov 06, 2019: FORMA announces poster presentation on FT-1101 at upcoming 2019 ASH Annual Meeting

Oct 10, 2019: Constellation Pharmaceuticals announces MANIFEST data updates will be provided in oral and poster sessions on December 9 at ASH

Jun 27, 2019: Zenith Epigenetics announces dosing of first patient in triple negative breast cancer trial with Pfizer

Jun 03, 2019: Interim data for CPI-0610 in MANIFEST clinical trial showed signals of clinical activity in Myelofibrosis patients

May 23, 2019: Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial

May 16, 2019: Constellation Pharmaceuticals provides interim update of data for CPI-0610 in ASCO and EHA abstracts

May 09, 2019: Nuevolution's BET-BD1 selective inhibitor and candidate compound, NUE20798, shows positive effect on disease scoring and biomarker levels in an atopic dermatitis (eczema) mouse model

Mar 18, 2019: Zenith Epigenetics announces U.S. FDA clearance of investigational new drug application for ZEN-3694 in TNBC program

Feb 21, 2019: A Nuevolution BET-BD1 selective inhibitor shows potential anticancer effect with immunotherapy in a mouse model of colorectal cancer

Jan 03, 2019: Constellation Pharmaceuticals provides update on MANIFEST clinical trial of CPI-0610 in mlyelofibrosis

Nov 01, 2018: Constellation Pharmaceuticals receives FDA Fast Track Designation for CPI-0610 in treatment of Myelofibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Boston Pharmaceuticals Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Constellation Pharmaceuticals Inc, H1 2020
Pipeline by Ningbo Wenda Pharma, H1 2020
Pipeline by Zenith Epigenetics Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

AbbVie Inc

Amgen Inc

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Constellation Pharmaceuticals Inc

Ningbo Wenda Pharma

Zenith Epigenetics Ltd

I would like to order

Product name: Bromodomain Containing Protein 2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/B249F5A05EB7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B249F5A05EB7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970